{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Standard+of+care+only&page=4", "query": { "intervention": "Placebo: Standard of care only", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 191, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Standard+of+care+only&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3A+Standard+of+care+only&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T22:14:27.260Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01086540", "title": "Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis-Associated PAH" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "CMRI", "type": "DIAGNOSTIC_TEST" }, { "name": "prednisone", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 57, "start_date": "2011-06-24", "completion_date": "2019-12-15", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 17, "location_summary": "Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086540" }, { "nct_id": "NCT03719430", "title": "APX005M and Doxorubicin in Advanced Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "APX005M", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexander Z. Wei, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-03-20", "completion_date": "2025-12-11", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 3, "location_summary": "Duarte, California • St Louis, Missouri • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719430" }, { "nct_id": "NCT05835206", "title": "Further MT for Antibiotic-Resistant Bacterial Colonization", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intestinal Multi-drug Resistant Organism Colonization" ], "interventions": [ { "name": "Microbiome Therapeutic", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-04-25", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Johns Creek, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05835206" }, { "nct_id": "NCT02633163", "title": "Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Low Dose Mesenchymal Stem Cells (MSCs)", "type": "DRUG" }, { "name": "High Dose Mesenchymal Stem Cells (MSCs)", "type": "DRUG" }, { "name": "Placebo Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 81, "start_date": "2018-11-18", "completion_date": "2026-02-03", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 9, "location_summary": "Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Manhasset", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02633163" }, { "nct_id": "NCT04331899", "title": "Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Peginterferon Lambda-1a", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 120, "start_date": "2020-04-25", "completion_date": "2021-05-06", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04331899" }, { "nct_id": "NCT03712345", "title": "Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Granulomatosis With Polyangiitis (GPA)", "Microscopic Polyangiitis (MPA)" ], "interventions": [ { "name": "IFX-1 low dose", "type": "DRUG" }, { "name": "IFX-1 high dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InflaRx GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-10-15", "completion_date": "2021-05-03", "has_results": true, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 33, "location_summary": "Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712345" }, { "nct_id": "NCT03337477", "title": "A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperkalemia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sodium Zirconium Cyclosilicate(ZS)", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Glucose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 70, "start_date": "2018-02-13", "completion_date": "2018-12-21", "has_results": true, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 12, "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Detroit, Michigan + 7 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03337477" }, { "nct_id": "NCT05228834", "title": "Voxelotor Neurocognitive Function Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Voxelotor Only Product in Oral Dose Form", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "8 Years to 18 Years" }, "enrollment_count": 1, "start_date": "2022-06-24", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05228834" }, { "nct_id": "NCT04537806", "title": "A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Respiratory Distress Syndrome", "COVID-19" ], "interventions": [ { "name": "Brexanolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sage Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2020-12-18", "completion_date": "2021-07-01", "has_results": true, "last_update_posted_date": "2022-08-19", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 9, "location_summary": "Fresno, California • Augusta, Georgia • Boston, Massachusetts + 6 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Massachusetts" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537806" }, { "nct_id": "NCT05454410", "title": "Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Treatment-Resistant Depression" ], "interventions": [ { "name": "MIJ821 Subcutaneous Injection 1 mg", "type": "DRUG" }, { "name": "MIJ821 Subcutaneous Injection 4 mg", "type": "DRUG" }, { "name": "MIJ821 Subcutaneous Injection 10 mg", "type": "DRUG" }, { "name": "Placebo Subcutaneous Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2023-03-13", "completion_date": "2023-11-28", "has_results": true, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-10-07T22:14:27.260Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland Park", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05454410" } ] }